Login to Your Account



Other News To Note


Wednesday, November 14, 2012
• CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7.1 showed promising safety and tolerability in heavily pretreated solid tumors. The compound also demonstrated signs of efficacy in most treated patients, suggesting longer overall survival in lung, hypopharnyx, ovarian, testicular, stomach, esophageal, biliary tract and neuroendocrine tumors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription